Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20682206 | 0.91 | CCR2 (0.34) | ATMNPC1DPP4JAK2JAK1 | |
| SCHEMBL20682201 | 0.84 | DPP4 (0.36) | ATMDPP4JAK2JAK1 | |
| SCHEMBL19014504 | 0.84 | JAK1 (0.37) | NPC1JAK2JAK1CCR2EPHX2 | |
| SCHEMBL19014058 | 0.81 | EPHX2 (0.32) | NPC1JAK2JAK1CCR2EPHX2 | |
| SCHEMBL20682393 | 0.80 | CCR2 (0.38) | NPC1JAK2JAK1CCR2 | |
| SCHEMBL22959671 | 0.78 | ATM (0.38) | ATMDPP4 | |
| SCHEMBL18806132 | 0.78 | ATM (0.38) | ATMDPP4 | |
| SCHEMBL20682320 | 0.78 | CHRM2 (0.34) | NPC1DPP4JAK1CCR2EPHX2 | |
| SCHEMBL20682222 | 0.78 | JAK2 (0.35) | ATMJAK2JAK1 | |
| SCHEMBL19014086 | 0.78 | NPC1 (0.34) | NPC1JAK1CCR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189836-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2019-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189836-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | ATM 1612/4885NPC1 870/4885DPP4 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.